Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Inoviq Ltd ( (AU:IIQ) ) is now available.
INOVIQ Ltd announced that Chairman David Williams will step down by year-end or upon the appointment of a new Chair, following the completion of a recent capital raising and the addition of a new Chinese cornerstone investor. Under Williams’ leadership, INOVIQ transitioned key programs from research to development, advanced its ovarian cancer test, and expanded commercialization of its exosome capture technology. The company is well-positioned to achieve its strategic objectives in the coming year, with a strengthened leadership team.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd is a leader in exosome technology, focusing on next-generation diagnostics and therapeutics to transform cancer care. The company’s product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 177,465
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$47.16M
For an in-depth examination of IIQ stock, go to TipRanks’ Overview page.